Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Menjugate infant B-cell response kinetics study
2004-004962-33Phase 4Completed
- Sponsor
- Chiron Corporation
- Start
- Feb 2005
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Meningococcal group C polysaccharide conjugate vaccine in meningococcal disease, sponsored by Chiron Corporation. Primary endpoints: Day of first detectability of meningococcal C-specific B cells after first and third immunization and Persistence and comparative plasma cell response after first and third vaccination. Started Feb 2005; status: completed.
02
Drugs
Meningococcal group C polysaccharide conjugate vaccine
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2004-004962-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004962-33.